Clinical Trials

  • Principal Investigator:

    Anne-Catrin Uhlemann, MD
    We want to examine if wastewater-based surveillance of SARS-CoV-2 is a valuable tool to detect SARS-CoV-2-positive individuals on campus prior to being identified by routine individual testing. We aim to enroll CU employees and students for active surveillance of SARS-CoV-2 carriage to be able to validate waste water surveillance findings. If successful this approach might inform targeted testing and can improve safety on campus.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD
    The purpose of this study is to look at whether these study drugs improve the bodys response to human immunodeficiency virus (HIV) in people with HIV (PWH) who started antiretroviral therapy (ART) early after getting HIV-1. The study treatments we are investigating are a study treatment vaccine, a study drug called vesatolimod (VES), and two broadly neutralizing antibodies (bNAbs; antibodies are natural proteins that the body makes in response to an infection), called GS-5423 and GS-2872. None of these experimental products has been approved by the US FDA except to be used in this research...
  • Principal Investigator:

    Jason E Zucker, MD
    The purpose of this study is to evaluate how well tecovirimat works for the treatment of human monkeypox virus infection and if the study drug is safe in people. Tecovirimat is approved by the Food and Drug Administration (FDA) to treat smallpox in adults and children, but its use in this study is considered investigational. Tecovirimat has been given safely to some people with monkeypox in the recent outbreak and is currently being studied in several ongoing studies outside of the US, but none of the studies have shown whether or not this study drug works to treat monkeypox. 530 people will...
  • Principal Investigator:

    Michael T Yin, MD
    Weight gain after starting antiretroviral therapy (ART) is common, but recent studies have found that some people living with HIV (PLWH) who are taking an integrase strand transfer inhibitor (INSTI) combined with tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir alafenamide/lamivudine (TAF/3TC) may gain more weight than people taking other drug combinations. A rising number of PLWH are overweight or obese. Higher body mass index and weight gain on ART increase the risk for diabetes, heart disease, and stroke. Researchers are looking to see if PLWH who have gained a significant amount...
  • Principal Investigator:

    Delivette Castor, PhD
    We want to learn more about how COVID-19 virus is spread in the community and in the households. To answer this question, we are looking for people who test positive for COVID to measure how many of their close contacts also test positive, and how long the virus persists in the household. We will also study risk factors for getting COVID-19.